Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Adaptive Randomized Trial of Enpatoran in Systemic and Cutaneous Lupus Erythematosus
2021-004648-27Phase 2Active
- Sponsor
- Merck KGaA
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and 1 more (3 arms), sponsored by Merck KGaA. Primary endpoint: Percent change from baseline in CLASI-A at Week 16. Started Nov 2021; status: active.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2021-004648-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004648-27.